Giulia Daneshgaran1,2, Connie B Paik2, Michael N Cooper2,3, Cynthia Sung2, Andrea Lo2, Wan Jiao2, Sun Young Park2, Gene H Kim4, Young-Kwon Hong5, Alex K Wong2,5. 1. Albert Einstein College of Medicine, Jack and Pearl Resnick Campus, New York, New York. 2. Division of Plastic and Reconstructive Surgery, Keck School of Medicine of University of Southern California, University of Southern California, Los Angeles, California. 3. Tulane University School of Medicine, New Orleans, Louisiana. 4. Department of Dermatology, Keck School of Medicine of University of Southern California, University of Southern California, Los Angeles, California. 5. Department of Surgery, Keck School of Medicine of University of Southern California, University of Southern California, Los Angeles, California.
Abstract
BACKGROUND AND OBJECTIVES: Previously, we have shown that 9-cis retinoic acid (9-cis RA) stimulates lymphangiogenesis and limits postsurgical lymphedema in animal models when administered via daily intraperitoneal injections. In this study, we investigate whether a single-use depot 9-cis RA drug delivery system (DDS) implanted at the site of lymphatic injury can mitigate the development of lymphedema in a clinically relevant mouse limb model. METHODS: Hind limb lymphedema was induced via surgical lymphadenectomy and irradiation. Animals were divided into two treatment groups: (1) 9-cis RA DDS, (2) placebo DDS. Outcomes measured included paw thickness, lymphatic clearance and density, epidermal thickness, and collagen deposition. RESULTS: Compared with control animals, 9-cis RA-treated animals had significantly less paw swelling from postoperative week 3 (P = .04) until the final timepoint at week 6 (P = .0007). Moreover, 9-cis RA-treated animals had significantly faster lymphatic clearance (P < .05), increased lymphatic density (P = .04), reduced lymphatic vessel size (P = .02), reduced epidermal hyperplasia (P = .04), and reduced collagen staining (P = .10). CONCLUSIONS: Animals receiving 9-cis RA sustained-release implants at the time of surgery had improved lymphatic function and structure, indicating reduced lymphedema progression. Thus, we demonstrate that 9-cis RA contained within a single-use depot DDS has favorable properties in limiting pathologic responses to lymphatic injury and may be an effective strategy against secondary lymphedema.
BACKGROUND AND OBJECTIVES: Previously, we have shown that 9-cis retinoic acid (9-cis RA) stimulates lymphangiogenesis and limits postsurgical lymphedema in animal models when administered via daily intraperitoneal injections. In this study, we investigate whether a single-use depot 9-cis RA drug delivery system (DDS) implanted at the site of lymphatic injury can mitigate the development of lymphedema in a clinically relevant mouse limb model. METHODS: Hind limb lymphedema was induced via surgical lymphadenectomy and irradiation. Animals were divided into two treatment groups: (1) 9-cis RADDS, (2) placebo DDS. Outcomes measured included paw thickness, lymphatic clearance and density, epidermal thickness, and collagen deposition. RESULTS: Compared with control animals, 9-cis RA-treated animals had significantly less paw swelling from postoperative week 3 (P = .04) until the final timepoint at week 6 (P = .0007). Moreover, 9-cis RA-treated animals had significantly faster lymphatic clearance (P < .05), increased lymphatic density (P = .04), reduced lymphatic vessel size (P = .02), reduced epidermal hyperplasia (P = .04), and reduced collagen staining (P = .10). CONCLUSIONS: Animals receiving 9-cis RA sustained-release implants at the time of surgery had improved lymphatic function and structure, indicating reduced lymphedema progression. Thus, we demonstrate that 9-cis RA contained within a single-use depot DDS has favorable properties in limiting pathologic responses to lymphatic injury and may be an effective strategy against secondary lymphedema.
Authors: M Skobe; T Hawighorst; D G Jackson; R Prevo; L Janes; P Velasco; L Riccardi; K Alitalo; K Claffey; M Detmar Journal: Nat Med Date: 2001-02 Impact factor: 53.440
Authors: Ya-Chen Tina Shih; Ying Xu; Janice N Cormier; Sharon Giordano; Sheila H Ridner; Thomas A Buchholz; George H Perkins; Linda S Elting Journal: J Clin Oncol Date: 2009-03-16 Impact factor: 44.544
Authors: Andrzej Szuba; Mihaela Skobe; Marika J Karkkainen; William S Shin; David P Beynet; Ned B Rockson; Noma Dakhil; Stan Spilman; Michael L Goris; H William Strauss; Thomas Quertermous; Kari Alitalo; Stanley G Rockson Journal: FASEB J Date: 2002-10-18 Impact factor: 5.191
Authors: Tuomas Tammela; Anne Saaristo; Tanja Holopainen; Johannes Lyytikkä; Anna Kotronen; Miia Pitkonen; Usama Abo-Ramadan; Seppo Ylä-Herttuala; Tatiana V Petrova; Kari Alitalo Journal: Nat Med Date: 2007-12-02 Impact factor: 53.440
Authors: Rachel Lentz; Christina Shin; Zoe Bloom; Kimiko Yamada; Young-Kwon Hong; Alex K Wong; Ketan Patel Journal: Lymphat Res Biol Date: 2021-02-05 Impact factor: 2.589
Authors: Stav Brown; Joseph H Dayan; Michelle Coriddi; Adana Campbell; Kevin Kuonqui; Jinyeon Shin; Hyeung Ju Park; Babak J Mehrara; Raghu P Kataru Journal: Front Pharmacol Date: 2022-01-25 Impact factor: 5.810
Authors: Annika D Smith; Geoffrey Paul Curtin; Nicholas C Allen; Pablo Fernandez-Penas; Alexander Hr Varey Journal: Australas J Dermatol Date: 2022-02-09 Impact factor: 2.481
Authors: Giulia Daneshgaran; Andrea Y Lo; Connie B Paik; Michael N Cooper; Cynthia Sung; Wan Jiao; Sun Y Park; Pauline Ni; Roy P Yu; Ivetta Vorobyova; Tea Jashashvili; Young-Kwon Hong; Gene H Kim; Peter S Conti; Yang Chai; Alex K Wong Journal: Sci Rep Date: 2019-12-04 Impact factor: 4.379